Anti-CGRP monoclonal antibodies in the treatment of migraine in women: impact on menstrual relared migraine and algodysmenorrhea

Background. Menstrual related migraine (MRM) occurs in 60% of women with migraine. These attacks are characterized by high intensity and poor response to abortive and prophylactic treatment. Hormonal therapy is one of the main treatment methods, but it has a large number of limitations. Increase in...

Olles dieđut

Bibliográfalaš dieđut

Váldodahkkit:	Anna V. Berdnikova, Natalya B. Kadymova, Nina V. Latysheva, Margarita V. Naprienko, Elena G. Filatova
Materiálatiipa:	Artigo
Giella:	Inglês
Almmustuhtton:	LLC "MEDIAFORMAT" 2023-10-01
Ráidu:	Клинический разбор в общей медицине
Fáttát:	migraine monoclonal antibodies erenumab fremanezumab cgrp menstrual-related migraine
Liŋkkat:	https://klin-razbor.ru/en/archive/2023/vol-4-10-2023/anti-cgrp-monoclonal-antibodies-in-the-treatment-of-migraine-in-women-impact-on-menstrual-relared-mi_6624/?element
Fáddágilkorat:	Lasit fáddágilkoriid Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!